CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

But CRISPR is a long-term story that is still in the early innings. The company has moved past its proof-of-concept phase, ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG recently reported its fourth-quarter and full-year 2025 results, showing revenue falling to US$0.864 million in Q4 and US$3.51 million for the year, alongside wider net losses ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.37 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.44 per share a year ago. These ...

Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.

CRISPR Therapeutics overview after recent trading moves CRISPR Therapeutics (CRSP) has seen mixed trading recently, with the ...